Description: Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Home Page: www.editasmedicine.com
11 Hurley Street
Cambridge,
MA
02141
United States
Phone:
617 401 9000
Officers
| Name | Title |
|---|---|
| Dr. Gilmore O'Neill M.D. | President, CEO & Director |
| Mr. Erick J. Lucera C.F.A., CPA | CFO & Executive VP |
| Dr. Linda C. Burkly Ph.D. | Executive VP & Chief Scientific Officer |
| Dr. Baisong Mei M.D., Ph.D. | Executive VP & Chief Medical Officer |
| Dr. Feng Zhang Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. George McDonald Church Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Mr. Gregory Whitehead | Executive VP and Chief Technical & Quality Officer |
| Cristi Barnett | Corporate Communications & Investor Relations |
| Ms. Charlene Stern J.D., Ph.D. | Executive VP & General Counsel |
| Ms. Linea Aspesi | Executive VP & Chief People Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9567 |
| Price-to-Sales TTM: | 2.5703 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 265 |